Re-Thinking Clinical Trials in Oncology
 Assessing the landscape of novel trial design for cancer therapies to improve data collection, enhance patient access, and drive clinical outcomes for breakthrough therapies

October 28, 2020 | Live Virtual Forum (EST)

Sandra Vingerhoedt

Clinical Project Manager Bayer AG, Belgium

I live in Belgium and have a master’s degree in Biomedical Sciences. I have been working in the pharmaceutical industry since graduating, for 18 years now. My main area of interest and activity has been oncology and I have been involved in all study stages ph I to ph IV. I have worked closely with sites as a CRA, later on a more global level as Study Manager and have been part of various many task force groups focusing on various operational aspects of clinical studies, e.g. data management, eCRF, site startup,... Currently I am overseeing multiple studies as Clinical Project Manager, ensuring long term planning and operational & budgetary alignment from program set-up to wind-down.

WEDNESDAY, OCTOBER 28

12:00 PM Post-trial Access to Treatment: The Opportunity Presented By Managed Access Programs

The rising cost of clinical development, coupled with the ethical obligation to ensure that patients exiting a clinical trial are able to remain on active treatment if necessary, has led some pharmaceutical and bio-pharmaceutical companies to review their trial protocols and consider alternative options. This session looks at some of the key considerations and how many companies are adopting different supply models.